Search results for " Clinical Trials as Topic"

showing 10 items of 39 documents

The effect of probiotics as a treatment for constipation in elderly people: A systematic review.

2016

Abstract Purpose Treating constipation in elderly people remains a challenge; the administration of probiotics may be a valid therapy for this problem as an alternative to traditional drug-based treatments. The objective of this systematic review was to evaluate the efficiency of probiotics in treating constipation in elderly people. Methods Articles related to this topic and published, without any time limitations, in the Medline, Embase, Scopus, Lilacs, or Cochrane databases were systematically reviewed according to Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. The primary search terms were ‘constipation’ and ‘probiotics’. The main inclusion crite…

MaleAgingmedicine.medical_specialtyHealth (social science)ConstipationMEDLINEAlternative medicinePlaceboGastroenterologylaw.invention03 medical and health sciencesProbiotic0302 clinical medicinelawInternal medicinemedicineHumans030212 general & internal medicineIntensive care medicineAgedAged 80 and overbusiness.industryClinical study designProbioticsSystematic review030211 gastroenterology & hepatologyObservational studyFemaleControlled Clinical Trials as TopicGeriatrics and Gerontologymedicine.symptombusinessGerontologyConstipationArchives of gerontology and geriatrics
researchProduct

Economic evaluation of a guided and unguided internet-based CBT intervention for major depression: Results from a multicenter, three-armed randomized…

2017

Depression is one of the most common mental disorders and will become one of the leading causes of disability in the world. Internet-based CBT programs for depression have been classified as well established following the American Psychological Association criteria for empirically supported treatments. The aim of this study is to analyze the cost effectiveness at 12-month follow-up of the Internet-based CBT program Smiling is fun with (LITG) and without psychotherapist support (TSG) compared to usual care. The perspective used in our analysis is societal. A sample of 296 depressed patients (mean age of 43.04 years; 76% female; BDI-II mean score = 22.37) from primary care services in four Sp…

MaleSpanish PeopleEconomicsPsychological interventionSocial SciencesSeverity of Illness Indexlaw.invention:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Learning and Memory0302 clinical medicineHispanoamericanosEthnicitiesPsychologyAnálisis de intención de tratarlcsh:Sciencemediana edadancianoDepressionAntidepressantsadulto:Health Care::Health Services Administration::Patient Care Management::Comprehensive Health Care::Primary Health Care [Medical Subject Headings]Humanosadulto joven:Health Care::Health Care Quality Access and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Epidemiologic Study Characteristics as Topic::Clinical Trials as Topic::Controlled Clinical Trials as Topic::Randomized Controlled Trials as Topic::Intention to Treat Analysis [Medical Subject Headings]Psicoterapia:Information Science::Information Science::Computing Methodologies::Computer Systems::Computer Communication Networks::Internet [Medical Subject Headings]medicine.medical_specialtyEvidence-based practiceGrupos control03 medical and health sciences:Health Care::Health Care Economics and Organizations::Economics::Costs and Cost Analysis::Cost-Benefit Analysis [Medical Subject Headings]Drug TherapySeverity of illnessHumans:Persons::Persons::Age Groups::Adult [Medical Subject Headings]psicoterapiaAgedPharmacologyDepressive DisorderDepressive Disorder MajorInternetPrimary Health CareMood Disorderslcsh:RBiology and Life SciencesSonrisa030227 psychiatryHealth CareAnálisis costo-beneficio:Check Tags::Female [Medical Subject Headings]Economic evaluationlcsh:QPopulation GroupingsNeuroscienceGerontologyFinancial ManagementCost effectivenessCost-Benefit Analysishumanosadolescentelcsh:MedicineTrastorno depresivoRandomized controlled triallawDepresiónMedicine and Health Sciences030212 general & internal medicineMultidisciplinaryAdultoPharmaceuticsresultado del tratamientoFemeninoDrugsCost-effectiveness analysisMiddle AgedTelemedicineTreatment OutcomeSociedades científicasFemale:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Communication::Nonverbal Communication::Facial Expression::Smiling [Medical Subject Headings]Estudios de seguimiento:Persons::Persons::Population Groups::Ethnic Groups::Hispanic Americans [Medical Subject Headings]telemedicinaResearch ArticleAdultAdolescent:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Methods::Research Design::Control Groups [Medical Subject Headings]:Psychiatry and Psychology::Behavioral Disciplines and Activities::Psychotherapy [Medical Subject Headings]Cost-Effectiveness AnalysisMEDLINEYoung Adulttrastorno depresivoAtención primaria de saludMental Health and PsychiatryIndirect CostsmedicineLearningíndice de gravedad de la enfermedadPrimary Care:Psychiatry and Psychology::Mental Disorders::Mood Disorders::Depressive Disorder [Medical Subject Headings]:Health Care::Health Care Economics and Organizations::Organizations::Societies::Societies Scientific [Medical Subject Headings]Cognitive Behavioral Therapybusiness.industryCognitive Psychology:Health Care::Health Care Quality Access and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Follow-Up Studies [Medical Subject Headings]Economic AnalysisPsychotherapyPeople and PlacesPhysical therapyCognitive Science:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Behavioral Symptoms::Depression [Medical Subject Headings]businessFinance
researchProduct

Efficacy of a blended low-intensity internet-delivered psychological programme in patients with multimorbidity in primary care: study protocol for a …

2019

BackgroundThe World Health Organization (WHO) has included comorbidity between depression and a chronic disease among the 10 leading global health priorities. Although there is a high prevalence of multimorbidity, health care systems are mainly designed for the management of individual diseases. Given the difficulty in delivering face-to-face psychological treatments, alternative models of treatment delivery have been proposed, emphasizing the role of technologies such as the Internet. The aim of this study is to assess the efficacy in Primary Care (PC) of a blended low-intensity psychological intervention applied using information and communication technologies (ICTs) for the treatment of …

MaleTecnología de la informaciónhumanosPsychological interventiondepresiónEnsayo clínico controlado aleatoriolaw.invention:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]dolor lumbarStudy Protocol0302 clinical medicineRandomized controlled triallawlcsh:PsychiatryDepresiónHealth careGlobal healthMedicine030212 general & internal medicineRandomized Controlled Trials as Topic:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Clinical Trials as Topic::Controlled Clinical Trials as Topic::Randomized Controlled Trials as Topic [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Evaluation Studies as Topic::Clinical Trials as Topic::Controlled Clinical Trials as Topic::Randomized Controlled Trials as Topic [Medical Subject Headings]:Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Chronic Disease [Medical Subject Headings]Depressionensayos clínicos controlados aleatorizados como asuntoMultimorbilidadadultoPrimary careLow back pain:Health Care::Health Services Administration::Patient Care Management::Comprehensive Health Care::Primary Health Care [Medical Subject Headings]Psychiatry and Mental healthdiabetes mellitus:Information Science::Information Science::Computing Methodologies::Computer Systems::Computer Communication Networks::Internet [Medical Subject Headings]:Diseases::Pathological Conditions Signs and Symptoms::Signs and Symptoms::Pain::Back Pain::Low Back Pain [Medical Subject Headings]Femalemedicine.symptomAdultmedicine.medical_specialtyenfermedad crónicalcsh:RC435-571:Check Tags::Male [Medical Subject Headings]03 medical and health sciencesInformation and communication technologies (ICTs)Atención primaria de saludIntervention (counseling)Humans:Persons::Persons::Age Groups::Adult [Medical Subject Headings]:Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings]InternetPrimary Health Carebusiness.industry:Diseases::Endocrine System Diseases::Diabetes Mellitus::Diabetes Mellitus Type 2 [Medical Subject Headings]Multimorbidity:Health Care::Health Care Facilities Manpower and Services::Health Personnel::Physicians::Physicians Primary Care [Medical Subject Headings]medicine.diseaseComorbidity030227 psychiatryClinical trial:Check Tags::Female [Medical Subject Headings]Diabetes Mellitus Type 2SpainChronic DiseasePhysical therapyRandomized controlled trial (RCT)business:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Behavioral Symptoms::Depression [Medical Subject Headings]Low Back PainBMC psychiatry
researchProduct

Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists

2010

Abstract Background Overall survival (OS) is the gold standard for the demonstration of a clinical benefit in cancer trials. Replacement of OS by a surrogate endpoint allows to reduce trial duration. To date, few surrogate endpoints have been validated in digestive oncology. The aim of this study was to draw up an ordered list of potential surrogate endpoints for OS in digestive cancer trials, by way of a survey among clinicians and methodologists. Secondary objective was to obtain their opinion on surrogacy and quality of life (QoL). Methods In 2007 and 2008, self administered sequential questionnaires were sent to a panel of French clinicians and methodologists involved in the conduct of …

OncologyCancer ResearchTime FactorsDigestive System Neoplasms[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineQuality of lifeSurveys and QuestionnairesMedicine030212 general & internal medicineMESH: Treatment OutcomeResponse rate (survey)MESH : Evidence-Based MedicineClinical Trials as TopicEvidence-Based MedicineMESH: Endpoint DeterminationMESH: Research DesignMESH : QuestionnairesMESH : Research Designlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthMESH: Reproducibility of Resultsmedicine.anatomical_structureTreatment OutcomeOncologyResearch Design030220 oncology & carcinogenesisData Interpretation StatisticalMESH: Survival AnalysisMESH : Disease-Free SurvivalMESH : Endpoint DeterminationFranceMESH : Time FactorsResearch Articlemedicine.medical_specialtyMESH: Clinical Trials as TopicEndpoint DeterminationRectum[SDV.CAN]Life Sciences [q-bio]/CancerMESH : Treatment Outcomelcsh:RC254-282Disease-Free Survival03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerInternal medicineGeneticsHumansMESH : Data Interpretation StatisticalMESH : FranceSurvival analysisMESH: Humansbusiness.industrySurrogate endpointMESH: Digestive System NeoplasmsMESH : Reproducibility of ResultsMESH: QuestionnairesMESH : HumansMESH: Time FactorsCancerReproducibility of ResultsMESH: Quality of LifeMESH : Quality of Lifemedicine.diseaseSurvival AnalysisMESH : Clinical Trials as TopicMESH: FranceLocalized diseaseEndpoint DeterminationMESH: Disease-Free SurvivalQuality of LifeMESH : Digestive System NeoplasmsMESH : Survival AnalysisbusinessMESH: Data Interpretation StatisticalMESH: Evidence-Based MedicineBMC Cancer
researchProduct

Non small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trials

2005

In the last two decades the results of medical treatment of advanced non-small cell lung cancer (NSCLC) have constantly improved even if they are still far from being considered satisfactory. Today systemic cisplatin-based chemotherapy (CT) is able to increase survival and improve cancer-related symptoms in patients with advanced ‘wet’ stage III and metastatic stage IV NSCLC, but it not clear if the benefits of CT also apply to patients with poor performance status (PS) [1, 2]. PS is the most powerful independent prognostic factor in advanced NSCLC since it is a reliable measure of functional independence, ability to perform daily activities and work, and a strong predictor of survival and …

Oncologymedicine.medical_specialtyLung Neoplasmsbusiness.industryDrugs Investigationallung cancer performance status 2 chemotherapy best supportive careHematologymedicine.diseaseClinical trialRegimenOncologyQuality of lifeCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansControlled Clinical Trials as TopicStage (cooking)Lung cancerbusinessAdverse effectSurvival rateSurvival analysisNeoplasm StagingAnnals of Oncology
researchProduct

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2).

2022

Abstract Antibody therapeutics can be associated with unwanted immune responses resulting in the development of anti‐drug antibodies (ADA). Optimal methods to evaluate the potential effects of ADA on clinical outcomes in oncology are not well established. In this study, we assessed efficacy and safety, based on ADA status, in patients from over 10 clinical trials that evaluated the immune checkpoint inhibitor atezolizumab as a single agent or as combination therapy for several types of advanced cancers. ADA can only be observed post randomization, and imbalances in baseline prognostic factors can confound the interpretation of ADA impact. We applied methodology to account for the confoundin…

Oncologymedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesRandomizationCombination therapyDatabases FactualMEDLINERM1-950Antibodies Monoclonal HumanizedGeneral Biochemistry Genetics and Molecular BiologyArticleAtezolizumabimmune system diseasesInternal medicineNeoplasmsmedicineHumansGeneral Pharmacology Toxicology and PharmaceuticsAdverse effectImmune Checkpoint InhibitorsClinical Trials as Topicbusiness.industryGeneral NeuroscienceImmunogenicityResearchConfoundingnutritional and metabolic diseaseshemic and immune systemsGeneral MedicineArticlesAntibodies Monoclonal Humanized/immunology; Antibodies Monoclonal Humanized/pharmacokinetics; Antibodies Neutralizing/immunology; Antibodies Neutralizing/metabolism; Clinical Trials as Topic; Databases Factual; Humans; Immune Checkpoint Inhibitors/immunology; Immune Checkpoint Inhibitors/pharmacokinetics; Neoplasms/drug therapy; Safety; Treatment OutcomeAntibodies NeutralizingClinical trialenzymes and coenzymes (carbohydrates)Treatment OutcomeTherapeutics. PharmacologyPublic aspects of medicineRA1-1270SafetybusinessClinical and translational science
researchProduct

Antibiotic prophylaxis in antenatal nonrefluxing hydronephrosis, megaureter and ureterocele

2012

Observation is a conservative management option in infants with nonrefluxing hydronephrosis, primary nonrefluxing megaureter and ureterocele diagnosed postnatally following antenatal detection of hydronephrosis. Antibiotic prophylaxis might be a sensible regimen under these circumstances to prevent UTI in this population who are potentially at increased risk. However, studies examining the efficacy of prophylactic antibiotics are sparse in this setting. For each condition, prophylactic policies seem extremely variable, and UTI rates vary widely with comparable rates reported between patients followed on and off antibiotics. Overall, antibiotic prophylaxis seems unnecessary in patients with …

Prenatal Diagnosimedicine.medical_specialtyHydronephrosiMegaureterUrologyPopulationmegaureterPrenatal diagnosisHydronephrosisurologic and male genital diseasesantanatal hydronefrosiPregnancyPrenatal Diagnosisantibiotics prophilaxis; antanatal hydronefrosis; megaureter; ureterocelemedicineAntibiotic ProphylaxiAnimalsHumansantibiotics prophilaxiAntibiotic prophylaxisRisk factoreducationHydronephrosiseducation.field_of_studyClinical Trials as TopicUreteroceleAnimalbusiness.industrySettore MED/20 - Chirurgia Pediatrica E InfantileAntibiotic Prophylaxismedicine.diseaseUreteroceleSurgeryRegimenFemaleAnimals; Antibiotic Prophylaxis; Clinical Trials as Topic; Female; Humans; Hydronephrosis; Pregnancy; Prenatal Diagnosis; Ureterocele; UrologybusinessHuman
researchProduct

The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway

2010

Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) have improved outcomes for patients with metastatic colorectal carcinoma. Among patients not carrying activating mutations in the KRAS gene, only a limited number will experience tumor response to these therapeutic agents. The role of BRAF mutations in determining resistance to this treatment is emerging through preclinical and clinical studies. Standardization and validation of laboratory mutation analysis is needed to allow an optimal use of anti-EGFR therapies in the management of colorectal carcinoma. Clinical single-arm and randomized studies were conducted both in first-line and refractory settings to evaluate…

Proto-Oncogene Proteins B-rafCancer ResearchPrognosiColorectal cancerCetuximabColorectal Neoplasmmedicine.disease_causeBRAFProto-Oncogene Proteins p21(ras)FOLFOXProto-Oncogene ProteinsAntineoplastic Combined Chemotherapy ProtocolsKRASmedicineHumansPanitumumabEpidermal growth factor receptorBRAF; Cetuximab; Colorectal carcinoma; KRAS; Panitumumab; Predictive factors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Humans; Mutation; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Receptor Epidermal Growth Factor; Signal Transduction; ras Proteins; Cancer Research; OncologyneoplasmsProto-Oncogene ProteinClinical Trials as TopicAntineoplastic Combined Chemotherapy ProtocolCetuximabbiologybusiness.industryPanitumumabGeneral Medicineras ProteinPrognosismedicine.diseasedigestive system diseasesOxaliplatinErbB ReceptorsColorectal carcinomaOncologyMutationras ProteinsCancer researchFOLFIRIbiology.proteinReceptor Epidermal Growth FactorKRASPredictive factorColorectal NeoplasmsbusinessHumanSignal Transductionmedicine.drugOncology
researchProduct

Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, a…

2008

Background We published the Canadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema (HAE; C1 inhibitor [C1-INH] deficiency) in 2004. Objective To ensure that this consensus remains current. Methods In collaboration with the Canadian Network of Rare Blood Disorder Organizations, we held the second Canadian Consensus discussion with our international colleagues in Toronto, Ontario, on February 3, 2006, and reviewed its content at the Fifth C1 Inhibitor Deficiency Workshop in Budapest on June 2, 2007. Papers were presented by international investigators, and this consensus algorithm approach resulted. Results This consensus algorithm …

Pulmonary and Respiratory MedicineConsensus algorithmmedicine.medical_specialtyCanadaC1 inhibitor deficiencyConsensus Development Conferences as TopicInternational CooperationImmunologyMEDLINEEcallantidemedicineImmunology and AllergyHumansHungarybusiness.industryAngioedemas HereditaryState of the art reviewEvidence-based medicinemedicine.diseaseBlood DisorderFamily medicineHereditary angioedemaControlled Clinical Trials as TopicbusinessAlgorithmsmedicine.drugAnnals of allergy, asthmaimmunology : official publication of the American College of Allergy, Asthma,Immunology
researchProduct

Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position…

2011

To cite this article: Baiardini I, Braido F, Bindslev-Jensen C, Bousquet PJ, Brzoza Z, Canonica GW, Compalati E, Fiocchi A, Fokkens W, Gerth van Wijk R, Giménez-Arnau A, Godse K, Grattan C, Grob JJ, La Grutta S, Kalogeromitros D, Kocatürk E, Lombardi C, Mota-Pinto A, Ridolo E, Saini SS, Sanchez-Borges M, Senna GE, Terreehorst I, Todo Bom A, Toubi E, Bousquet J, Zuberbier T, Maurer M. Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper. Allergy 2011; 66: 840-844. ABSTRACT: The aim of this Global Allergy and Asthma European Network (GA(2) LEN) consensus report is to provide recommendations …

QuestionnairesClinical Trials as TopicUrticariaQuestionnaireGa2LenhumanitiesOutcome Assessment (Health Care)Treatment Outcomeimmune system diseasesSurveys and QuestionnairesOutcome Assessment Health Careparasitic diseasesChronic DiseaseQuality of LifeHumansQuestionnaires; Humans; Treatment Outcome; Clinical Trials as Topic; Quality of Life; Urticaria; Outcome Assessment (Health Care); Chronic DiseaseUrticáriaskin and connective tissue diseasesHumanQualidade de Vida
researchProduct